key: cord-0027789-4nitwoog
authors: Reese, Charles F.; Chinnakkannu, Panneerselvam; Tourkina, Elena; Hoffman, Stanley; Kuppuswamy, Dhandapani
title: Multiple subregions within the caveolin-1 scaffolding domain inhibit fibrosis, microvascular leakage, and monocyte migration
date: 2022-02-25
journal: PLoS One
DOI: 10.1371/journal.pone.0264413
sha: bdf724587167e867cab10935ba07fa2932c1084e
doc_id: 27789
cord_uid: 4nitwoog

The caveolin-1 scaffolding domain (CSD, amino acids 82–101 of caveolin-1) has been shown to suppress bleomycin-induced lung and skin fibrosis and angiotensin II (AngII)-induced myocardial fibrosis. To identify active subregions within CSD, we split its sequence into three slightly overlapping 8-amino acid subregions (82–89, 88–95, and 94–101). Interestingly, all three peptides showed activity. In bleomycin-treated mice, all three subregions suppressed the pathological effects on lung and skin tissue morphology. In addition, while bone marrow monocytes isolated from bleomycin-treated mice showed greatly enhanced migration in vitro toward CXCL12, treatment in vivo with CSD and its subregions almost completely suppressed this enhanced migration. In AngII-induced heart failure, both 82–89 and 88–95 significantly suppressed fibrosis (both Col I and HSP47 levels), microvascular leakage, and heart weight/ body weight ratio (HW/BW) while improving ventricular function. In contrast, while 94–101 suppressed the increase in Col I, it did not improve the other parameters. The idea that all three subregions can be active depending on the assay was further supported by experiments studying the in vitro migration of human monocytes in which all three subregions were extremely active. These studies are very novel in that it has been suggested that there is only one active region within CSD that is centered on amino acids 90–92. In contrast, we demonstrate here the presence of other active regions within CSD.

Caveolin-1 is a structural cytoplasmic membrane protein involved in the formation/function of caveolae [1] . Besides its role in endocytosis and receptor trafficking, caveolin-1 is a master regulatory protein that inhibits a wide range of kinases and also eNOS and NADPH oxidase by binding to these proteins via the caveolin-1 scaffolding domain (CSD, amino acids 82-101) [2] [3] [4] [5] [6] [7] [8] [9] . CSD treatment is beneficial in mouse model systems (e.g. lung fibrosis, heart failure) in that it suppresses fibrosis, microvascular leakage, and inflammation. These effects are mediated by CSD's ability to act as a surrogate for caveolin-1, thereby reversing the effects of low caveolin-1 associated with fibrosis in vitro and in vivo in fibroblasts, monocytes, and mesenchymal stem cells [8, [10] [11] [12] [13] [14] [15] [16] [17] . In contrast, in endothelial cells CSD may have beneficial effects by acting as a competitor of the function of caveolin-1. This dual function of CSD has been suggested previously by many authors [18] [19] [20] .

In previous studies, we have shown the beneficial effects of CSD treatment in multiple mouse models: heart failure (HF) induced by either transverse aortic constriction or angiotensin II (AngII) infusion [21, 22] ; kidney fibrosis induced by AngII [21] ; bleomycin-induced lung and skin fibrosis [12, 13, 15, 16, 23] ; and aging-associated fibrosis of the heart, kidney, and brain [24] . These observations make CSD a rational candidate for development as a treatment for the many human diseases involving organ fibrosis and/or microvascular leakage (e.g. HF [14] To better understand the structure-activity relationship of CSD and to promote its development as a drug, here we have evaluated the activity of three independent subregions (amino acids 82-89, 88-95, 94-101) of caveolin-1. In general, shorter peptide drug candidates such as these are advantageous because they are easier to synthesize and should exhibit increased tissue penetration and decreased immunogenicity and other side effects [42, 43] . While some previous literature predicted that only 88-95 would have beneficial effects [44] [45] [46] , we present extensive evidence here that all three subregions can be active.

Mice were maintained at constant room temperature (20-22˚C) with free access to water and food under a 12:12 h light: dark cycle. All animal experiments were performed under a protocol approved by the Medical University of South Carolina (MUSC) Institutional Animal Care and Use Committee (IACUC).

Ten-week old, C57/BL6 mice (Charles River Laboratories, Boston, MA) were maintained under pathogen-free conditions. Briefly, osmotic minipumps (ALZET 1007D; DURECT Corporation, Cupertino, CA) containing either 100 μl saline vehicle or bleomycin (100 U/kg) designed to deliver their contents at 0.5 μl/h for 7 days were implanted under isofluorane anesthesia under the loose skin on the back of the mice slightly caudal to the scapulae as we have described [47] . Pumps containing bleomycin or vehicle were removed on day 8 and replaced with pumps containing the indicated peptides (n = 6 per group). After 14 more days, mice were sacrificed by isoflurane overdose, systemically perfused with PBS via the left ventricle, and lung and skin tissue harvested. Skin tissue was harvested adjacent to the main body of the pump.

For histology, lung lobes were perfused with buffered zinc formalin fixative (Z-Fix; Anatech, Battle Creek, MI). Lung lobes and skin strips were further fixed overnight in Z-Fix, then embedded in paraffin. Sections (4 μm) were stained with hematoxylin and eosin (H&E) or Masson's trichrome or immunohistochemically. Bone marrow (BM) monocytes were isolated for use in migration experiments as we described [21] . In these experiments, both activation (due to bleomycin treatment) and treatment with CSD and subregions occurs in vivo. Healthy human monocytes were isolated and activated with TGFβ (45 min, 10 ng/ml in RPMI 1640/1% BSA) as we described [15] . Migration experiments with both mouse and human monocytes were performed as we have described [15] . Briefly, CXCL12 (100 ng/ml in RPMI 1640/1% BSA) or unsupplemented RPMI 1640/1% BSA was placed into the lower wells of Neuro Probe Multiwell Chemotaxis Chambers (Neuro Probe, Gaithersburg, MD) fitted with 5-μm pore size polycarbonate filters. 25 μl of cell suspension (5 × 10 5 cells/ml) was placed in the upper wells. Peptides at the indicated concentrations were added to the cell suspension prior to placement. After incubation (2.5 h, 37˚C, 5% CO 2 ), filters were removed, fixed, and stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA). Cells on the underside of the membrane were photographed and counted in six high power fields per condition.

Wild-type C57BL/6J male mice (3 months) were purchased from Jackson Laboratory (Bar Harbor, Maine). Mini-osmotic pumps (ALZET 1002; DURECT Corporation, Cupertino, CA) were implanted as described above. The pumps contained either 100 μl saline or AngII (2.1 mg/kg/day) and delivered their contents at 0.25 μl/h for 2 wk. After two weeks, heart function was evaluated by echocardiography. Mouse sacrifice and sequential preparation of RIPA-soluble and RIPA-insoluble fractions for Western blotting were performed as previously described [22, 48] . As in previous studies, HSP47 and IgG Heavy Chain Western blots were performed using the soluble fraction and Col I Western blots were performed using the insoluble fraction. This sequential extraction provides better resolution by SDS-PAGE and the enrichment of these proteins in the fractions in which they are most abundant. Measurements of heart weight (in mg) and body weight (in g) were used to calculate the HW/BW ratio as previously described [22, 48] .

Echocardiography was performed using a Vevo2100 imaging system (VisualSonics, Toronto) as we described [22, 48] . Briefly, isoflurane anesthesia was used and heart rate was maintained at 400-500 bpm. Two-dimensional B-and M-mode analyses were performed using the 22-55 MHz linear transducer probe and VisualSonics 1.2.0 software. M-mode images of the parasternal short-axis view at papillary level was used to calculate ejection fraction (EF) and fractional shortening (FS). B-mode images of the parasternal long-axis were used to calculate stroke volume (SV) and cardiac output (CO). Tissue Doppler was used in the short-axis view at the papillary muscle level to obtain velocity of posterior left ventricular (LV) wall motion. 5 to 10 cycles were recorded to calculate isovolumic relaxation time (IVRT).

The sequence of peptides purchased from Elim Biopharmaceuticals (Hayward, CA) are shown in Table 1 . Peptides were dissolved in DMSO. In the bleomycin experiment, peptides in DMSO were diluted 10-fold with saline so that osmotic minipumps loaded with 100 μl delivered 8 μmol/kg over two weeks. In the AngII experiment, peptides in DMSO were diluted 100-fold with saline so that daily i.p. injections of 100 μl delivered 0.8 μmol/kg per day.

Values are presented as mean ± SEM. Differences were analyzed between groups using oneway analysis of variance (ANOVA) followed by a post hoc Tukey's multiple comparison to determine statistical significance.

We previously demonstrated that CSD (aa 82-101 of caveolin-1) has a wide range of beneficial effects in two distinct mouse heart failure models (TAC and AngII-induced disease) and in bleomycin-induced lung [16] and skin fibrosis [12] . In order to evaluate the Structure-Activity Relationship for CSD, we have divided it into three, slightly overlapping peptides of equal length (82-89, 88-95, and 94-101) and tested them in multiple systems in vivo (mouse lung and skin fibrosis, heart fibrosis) and in vitro (human monocyte migration). Whereas some previous studies concluded that only 88-95 should be active [46], we find significant activity in all three subregions.

We found that delivering bleomycin to mice via subcutaneously implanted osmotic minipumps results in a disease very similar to human SSc [47]. These similarities include: both lung and dermal fibrosis are observed, the lung fibrosis is accompanied by relatively little inflammation as compared to when bleomycin is delivered intratracheally, and dermal fibrosis is accompanied by a loss of transdermal fat.

To determine the beneficial effects of CSD subregions on bleomycin-induced lung fibrosis, when pumps delivering bleomycin were removed seven days after implantation, they were replaced with pumps delivering CSD or the subregions for the next two weeks. This is a therapeutic protocol because the potentially beneficial treatments are begun only after disease has been induced. Images of tissue morphology are shown in Fig 1A and To determine whether this effect might involve the inhibition of the migration of BMderived monocytes into the lung, BM monocytes were isolated from these six groups of mice and their ability to migrate toward the chemokine CXCL12 in vitro was determined. The migration of BM monocytes from bleomycin-treated mice was enhanced four-fold compared to control, saline-treated mice. This enhancement of migration was almost completely reversed in mice treated in vivo with CSD, 82-89, 88-95, or 94-101 ( Fig 1C) .

To validate this effect of CSD subregions on monocyte migration using human cells, peripheral monocytes were isolated from healthy donors and activated using TGFβ. CSD and all three subregions exhibit dose-dependent inhibition of TGFβ-induced migration even at extremely low concentrations while scrambled CSD (Table 1 ) was inactive (Fig 2) . Again, 82-89 was the most active while CSD, 88-95, and 94-101 were similar in activity to each other. 

Bleomycin causes a remarkable thickening of the dermis and thinning of the intradermal fat layer (lipoatrophy) in mice [12] just as occurs in SSc patients [50] . While all versions of CSD tested were effective in suppressing dermal thickening and lipoatrophy, CSD and 82-89 were the most effective (Fig 3) .

We have previously demonstrated that AngII-treated mice exhibit heart failure in terms of cardiac hypertrophy, fibrosis, microvascular leakage, and ventricular function and that all of these effects are suppressed by CSD [21] . When we evaluated 82-89, 88-95, and 94-101 in the AngII model, we found that 82-89 and 88-95 were effective in suppressing the pathological effects of AngII on cardiac hypertrophy (HW /BW ratio), IVRT, EF, FS, CO, and SV; while 94-101 and scrambled CSD were not effective (Fig 4) . We next evaluated fibrosis in terms of Col I and HSP47 levels and microvascular leakage in terms of IgG Heavy Chain levels ( Fig 5) . Again, CSD, 82-89, and 88-95 almost completely blocked the pathological changes in HSP47 and microvascular leakage while 94-101 had no effect. In contrast, all three subregions had a beneficial effect on Col I accumulation (Fig 5) .

In previous studies, we have shown the beneficial effect of CSD treatment on heart fibrosis and function using the transverse aortic constriction (TAC) model [22] , heart and kidney fibrosis In accord with these previous studies, our peptide 88-95 is active in a variety of assays. However, we also find extensive evidence that our peptides 82-89 and 94-101 represent active subregions of CSD. In the bleomycin model, all three subregion peptides were effective in inhibiting lung fibrosis, skin fibrosis, and the migration in vitro of BM monocytes derived from these mice. Similarly, all three peptides inhibited the migration of human monocytes in vitro. In the AngII model for HF, both 82-89 and 88-95 were effective in suppressing the deleterious effects of AngII on HW/BW ratio, ventricular function (IVRT, EF, FS), fibrosis (Col I and HSP47 levels), and microvascular leakage although in some cases 88-95 is somewhat more active. While 94-101 did not show any beneficial effects in the AngII model in most assays, it did have a significant ability to inhibit Col I accumulation. 

CSD peptides have been synthesized in different ways for use in different published studies. It was initially assumed both for studies in mice and in cell culture that attachment to the 16-amino acid insect Antennapedia Internalization Sequence was required for CSD to enter [2, 20, 46] .

Research groups have also differed in their capping of the C-terminus and N-terminus of CSD. For example, our peptides (Table 1 ) are capped at the C-terminus with an NH2 group while caps are not reported to be present on the peptides in a recent study whose results differed from ours [46] . In this study, 89-95 (called CSP7) was shown to inhibit fibrosis in vivo and in fibroblast cultures and to inhibit epithelial cell apoptosis in vivo, while 82-88 (called CSP3) and 96-101 (called CSP5) were inactive. Reasons that could be responsible individually or in combination to explain the difference between their results and ours include: 1) There are one or two amino acid differences between our peptides 82-89, 88-95, and 94-101 and their peptides 82-88, 89-95, and 96-101; 2) Our peptides are capped with a C-terminal NH2 group while their peptides are not reported to be capped; 3) Reasons "1" and/or "2" may lead to their peptides 82-88 and 96-101 not being able to enter cells; and 4) Although our 82-89 inhibits Col I accumulation in vivo, this may be an indirect effect due to its ability to inhibit microvascular leakage. In other words, the primary cellular target of 82-89 may be endothelial cells and it may have little direct effect on Col I expression by myofibroblasts. Thus, discrepancies between our study and other studies may depend on the presence or absence of modifications such as the Antennapedia sequence and/or C-terminal capping. In any case, it seems rather more likely that our inclusion of a C-terminal cap on 82-89 and 94-101 has revealed their beneficial effects as opposed to creating a false positive beneficial effect.

A key factor in understanding the function of CSD is the observation that CSD cannot form oligomers and cannot incorporate into the caveolin-1 oligomers that coat caveolae [53] . The CSD sequence within full-length caveolin-1 tethers a variety of kinases to plasma membrane caveolae or to the Golgi network and regulates their activities. However, free CSD may regulate kinases that are not membrane-bound or, alternatively, may cause kinases not to be tethered to the membrane via direct competition with CSD within full-length caveolin-1. The fact that the sites where CSD and its subregions can act are not limited to membranes may result in its activity at very low concentrations such as the inhibition of monocyte migration in vitro that we observed at sub-picogram levels of peptides (Fig 2) .

Caveolin-1 and CSD regulate multiple molecular mechanisms relevant to microvascular leakage and fibrosis. The presence of IgG heavy chain in tissue extracts was used as a marker for microvascular leakage. Mechanisms underlying endothelial barrier function loss include eNOS/NO/ROS/ NADPH Oxidase signaling and tyrosine kinase signaling [54] [55] [56] . An increased ROS:NO ratio activates receptor (e.g. PDGFR, VEGFR) and non-receptor tyrosine kinases (e.g. Pyk2, c-Src, FAK) resulting in decreased barrier function and promoting microvascular leakage [6, [57] [58] [59] [60] [61] . Because caveolin-1 and CSD regulate eNOS, NADPH Oxidase, and non-receptor and receptor tyrosine kinases [3, 44, 51, 62] , the ability of CSD and its subregions to suppress microvascular leakage may be mediated directly through its effects on tyrosine kinases or indirectly through its effects on NO:ROS signaling which in turn regulates tyrosine kinase activation.

We showed many years ago that caveolin-1 and CSD directly target fibrosis via pathways involving PKCα, PKCε, MEK, ERK, JNK, p38, and Akt that regulate Col I overexpression by myofibroblasts [8, 16] . Here we used Col I and the collagen chaperone HSP47 as markers for fibrosis. Besides the direct effects of CSD on fibrosis via these kinases, our more recent studies [21, 24] and the current study indicate that caveolin-1 and CSD also may indirectly regulate fibrosis via their effects on endothelial cells. When the permeability barrier function of endothelial cells is compromised, the resulting microvascular leakage promotes inflammation which may involve the recruitment of monocytes into injured tissue and their differentiation into fibrocytes/ myofibroblasts through mechanisms involving ERK, Smad 2/3, TGFβRI and RII, CXCR4, Lyn, and Src [63, 64] . In addition, fibrocytes secrete pro-fibrogenic factors that activate Col I expression by resident fibroblasts [65] . In summary, the ability of CSD to directly and indirectly regulate fibrosis involves multiple cellular and molecular targets. While it remains to be demonstrated, this complexity could further involve subregions of CSD differentially affecting various targets. Further, this differential effect could depend on the cell type being studied; and in the case of fibroblasts it could depend on their origin (e.g. resident fibroblasts vs fibrocyte-derived fibroblasts).

In summary, the current translational research on CSD subregions is novel because, to the best of our knowledge, this is the first study to demonstrate that the 82-89 and 94-101 subregions are active in vivo. Therefore, 82-89 and 94-101, like 88-95, may be the basis for novel treatments for the wide range of diseases involving fibrosis and/or microvascular leakage. 

The caveolin proteins

Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system

Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins

Down-regulation of caveolin-1, an inhibitor of transforming growth factor-beta signaling, in acute allergen-induced airway remodeling

Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide

Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities

Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation. Circulation research

Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling

Increased circulating fibrocytes in asthma with chronic airflow obstruction

Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis

Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis

Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis

Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide

Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo

eNOS uncoupling and endothelial dysfunction in aged vessels

Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis

Caveolin-1 opens endothelial cell junctions by targeting catenins

Control of vascular permeability by adhesion molecules

Caveolin-1 regulates expression of junction-associated proteins in brain microvascular endothelial cells

Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli

Caveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species

Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1

Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease

Fibrocytes in health and disease